Medtronic Stock

$92.81

0.92%

NYSE, Aug 29, 11:07 pm CET

ISIN

IE00BTN1Y115

Symbol

MDT

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Medtronic Stock price

$92.81

-14.66 13.64% 5Y

NYSE, Closing price Fri, Aug 29 2025

+0.85 0.92%

ISIN

IE00BTN1Y115

Symbol

MDT

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$119.0b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

25.6 | 16.4

P/S

3.5 | 3.3

EV/Sales

- | -

EV/FCF

P/B

Dividends

DPS

$2.80

Yield 1Y | 5Y

3.0% | 2.7%

Growth 1Y | 5Y

1.4% | 5.3%

Payout 1Y | 3Y

77.6% | 90.1%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$34.2b | $36.1b

EBITDA

$8.6b | $10.3b

EBIT

$6.8b | $9.0b

Net Income

$4.7b | -

Free Cash Flow

$5.3b

Growth (TTM | estimate)

Revenue

5.0% | 7.6%

EBITDA

10.0% | 23.1%

EBIT

9.9% | 37.4%

Net Income

18.7% | -

Free Cash Flow

3.1%

Financial Health

Equity Ratio

52.4%

Return on Equity

9.7%

ROCE

ROIC

Debt/Equity

EPS

$3.6

FCF per Share

Short interest

1.1%

Employees

95k

Rev per Employee

$350.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Medtronic Stock Analysis

Unlock Scores for Free

??

39 Analysts have issued a Medtronic forecast:

21x Buy

54%

17x Hold

44%

More details on Analyst Estimates Including Price Targets

39 Analysts have issued a Medtronic forecast:

Buy

54%

Hold

44%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Medtronic

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jul '25		+/- %
Revenue	34,200 34,200	5% 5% 100%
- Direct Costs	11,833 11,833	5% 5% 35%
Gross Profit	22,367 22,367	5% 5% 65%
- Selling and Administrative Expenses	10,963 10,963	3% 3% 32%
- Research and Development Expense	2,782 2,782	1% 1% 8%
EBITDA	8,603 8,603	10% 10% 25%
- Depreciation and Amortization	1,852 1,852	10% 10% 5%
EBIT (Operating Income) EBIT	6,751 6,751	10% 10% 20%
Net Profit	4,660 4,660	19% 19% 14%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Medtronic Stock News

Positive

The Motley Fool

●

2 days ago

3 Best Dividend Stocks to Buy Now

One of the highest honors among dividend stocks is to be a Dividend Aristocrat®, which requires 25 consecutive years or more in annual increases. The title Dividend Aristocrat is such a big deal that the term is a registered trademark of Standard & Poor's Financial Services LLC.

Neutral

PRNewsWire

●

3 days ago

Medtronic executives to speak at upcoming investor conferences

GALWAY, Ireland , Aug. 29, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference Thursday, September 4, 2025, at 8:00 a.m. EDT (7:00 a.m.

Positive

Seeking Alpha

●

5 days ago

Best Dividend Aristocrats For September 2025

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return...

More Medtronic News

Company Profile

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Head office	United States
CEO	Geoffrey Martha
Employees	95,000
Founded	2014
Website	www.medtronic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now